Cyfip1 is downregulated in acute lymphoblastic leukemia and may be a potential biomarker in acute lymphoblastic leukemia.

Abstract

The aim of the present study was to analyze the expression of Cyfip1 in acute lymphoblastic leukemia (ALL) and its correlations with clinical pathologic features. A total of 86 ALL samples and 32 normal peripheral blood lymphocyte (PBL) samples were enrolled in our study. mRNA expression of the Cyfip1 was assessed by real-time fluorescent relatively quantitative PCR, and Cyfip1 protein expression was evaluated by Western blot analysis. As a result, both mRNA and protein expression levels of Cyfip1 were significantly lower in ALL patients than those in the control samples (P = 0.025 and 0.000, respectively). Moreover, both mRNA and protein expression of both had an inverse relation with lymph node metastasis (P = 0.015 and 0.007, respectively), In conclusion, detecting mRNA and protein expression of Cyfip1 could provide clinically significant information relevant to diagnosis, progression, and treatment modalities for ALL, and Cyfip1 may serve as a potential biomarker for diagnosis and prognosis in ALL.

• Authors: Xu Chen, Lingyan Qin, Ping Li, Wuning Mo
• Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) Vol. 37 Issue 7 Pg. 9285-8 (Jul 2016) ISSN: 1423-0380 [Electronic] Netherlands
• PMID: 26779626 (Publication Type: Journal Article)

Chemical References

• Adaptor Proteins, Signal Transducing
• Biomarkers, Tumor
• CYFIP1 protein, human
• RNA, Messenger

Topics

• Adaptor Proteins, Signal Transducing (genetics)
• Adolescent
• Biomarkers, Tumor (genetics)
• Child
• Down-Regulation (genetics)
• Female
• Humans
• Lymphatic Metastasis (genetics, pathology)
• Male
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics, pathology)
• Prognosis
• RNA, Messenger (genetics)